Peptide Notes: the company a molecule keeps
I had pencilled in GHK for the hair-growth result. Then the second ingredient demanded attention. Copper, carriers and binding partners deserve their places too.
GHK-Cu and copper
A copper-bound peptide, a mixed hair preparation and small human skin studies.
Copper and skin studies ›KPV carriers and combinations
Protective particles, a cell transporter and a second active drug in mouse experiments.
The assembled preparations ›Semaglutide and albumin
Binding to a blood protein helps a gut-hormone medicine remain in circulation.
Binding and patient outcomes ›Tirzepatide receptor targets
A single peptide acting at GIP and GLP-1 receptors, tested in direct patient comparisons.
Dual action in trials ›GHK in the hair-study mixture
A six-month trial in 45 men with inherited hair loss tested a preparation containing GHK and 5-aminolevulinic acid. Hair counts increased more with that combination than with placebo. No adverse events were reported in any group.
I crossed out the solo credit. The study could establish an effect of the mixture, while leaving the individual contribution of GHK unresolved. It also tested GHK in that complex, rather than pure GHK-Cu. The mixture earns a narrower conclusion from me.
Peptide Notes grew from an interest in those accompanying parts. A compound name can occupy the headline while a second active ingredient, a metal or a carrier does consequential work inside the experiment. The different relationships deserve names of their own.
Copper and protective carriers
GHK-Cu has its companion in the name: GHK bound to copper. Researchers study how the complex affects skin cells, and a laboratory experiment measured copper crossing and remaining in removed human skin. The topical review examines small human skin studies alongside the difficulty of getting the material through the skin barrier.
KPV brings a different sort of accompaniment. Nanoparticles inside a protective gel helped deliver KPV to inflamed bowel in mice. A later experiment paired KPV with an immunosuppressant in a targeted preparation, improving mouse colitis outcomes beyond either agent alone.
I regard that second experiment as a collaboration between active ingredients and delivery design. The result belongs to the assembled preparation. The KPV article follows the transporter, the gel and the combination separately; each contributes a different question.
Blood proteins and receptor targets
For semaglutide, an attached fatty part helps the medicine bind albumin, a blood protein, and remain in circulation. The semaglutide clinical review gives the background to a gut-hormone signal altered to last longer. Albumin is a circulating binding partner, rather than another active drug mixed into the medicine.
Tirzepatide also binds albumin and activates receptors for two gut hormones, GIP and GLP-1. The clinical reference describes one peptide acting at both receptor targets. This is a dual action of a single molecule. The receptors are destinations for its activity, whereas copper is part of the GHK-Cu complex and the KPV combination contains another drug.
I separate these arrangements by their chemistry. Their attraction is precisely how different they are: a bound metal, a protected cargo, a co-treatment, a blood protein and receptor targets.
Clinical outcomes
The human trials give these relationships practical stakes. Semaglutide trials measured weight change, cardiovascular events and a kidney-disease composite in separate populations. The direct obesity comparison with tirzepatide found greater average weight loss with tirzepatide under its treatment conditions.
Those findings carry substantially more weight for patient benefit than KPV's cell and mouse experiments or broad extrapolations from small GHK-Cu skin studies. Adverse effects and the finished product still belong in the account.
The comparison of mixtures and binding partners gathers the relationships together. I remain absorbed by these chemical partnerships, even where human evidence runs out. Assigning each finding to the preparation actually tested makes the subject more interesting.